← Back to Clinical Trials
Recruiting NCT07010341

NCT07010341 Quantitative Intra-operative Assessment of Parathyroid Perfusion Using Indocyanine Green (ICG) Fluorescence Imaging

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07010341
Status Recruiting
Phase
Sponsor Fujian Medical University
Condition Thyroid Surgery
Study Type OBSERVATIONAL
Enrollment 210 participants
Start Date 2025-05-01
Primary Completion 2025-11-30

Trial Parameters

Condition Thyroid Surgery
Sponsor Fujian Medical University
Study Type OBSERVATIONAL
Phase N/A
Enrollment 210
Sex ALL
Min Age N/A
Max Age N/A
Start Date 2025-05-01
Completion 2025-11-30
Interventions
ntra-operative Indocyanine Green (ICG) Fluorescence Quantification

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This single-center, prospective, three-phase observational cohort quantifies the relationship between indocyanine green (ICG) fluorescence and early parathyroid function. Adult patients scheduled for unilateral thyroid lobectomy with autotransplantation of the ipsilateral inferior parathyroid gland are enrolled. After intravenous ICG 25 µg/kg, peak fluorescence of the superior parathyroid gland and the common carotid artery (CCA) is recorded at 60-120 seconds to calculate the ratio R = PTG/CCA. Serum parathyroid hormone (PTH) is measured 30 minutes post-operatively. A derivation cohort (\~120 patients) generates R-based thresholds for in-situ preservation versus autotransplantation, which are prospectively validated in an independent cohort (60 patients) together with decision-curve analysis of clinical net benefit.

Eligibility Criteria

Inclusion Criteria: * Scheduled for unilateral thyroid lobectomy plus central (VI-level) lymph-node dissection. * Intra-operative findings consistent with: * Complete identification and in-situ preservation of the ipsilateral superior parathyroid gland; * Complete identification and autotransplantation of the ipsilateral inferior parathyroid gland. * Serum 25-hydroxy-vitamin D ≥ 30 ng/mL at baseline; patients below this level may be enrolled after standardized vitamin-D and calcium supplementation with re-test confirming ≥ 30 ng/mL. * Surgery and all postoperative follow-up performed at the study center. * Able and willing to provide written informed consent. Exclusion Criteria: * Prior surgery on the thyroid or parathyroid glands. * Severe hepatic or renal impairment, or other serious metabolic bone disease. * Pregnancy or lactation. * Known hypersensitivity to indocyanine green or iodine-containing compounds. * Inability or unwillingness to comply with postoperative visits and blood

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology